Abstract
Aaron Kithcart, Calum A. MacRae
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cardiac arrhythmias: the quest for a cure: a historical perspective
2004
Drug-induced prolongation of the QT interval
10.1056/nejmra032426 · 2004
The Cardiac Arrhythmia Suppression Trial
10.1056/nejm198912213212510 · 1989
Small molecule and peptide therapies for chronic heart failure: a patent review (2011-2014)
10.1517/13543776.2015.1061997 · 2015
Contemporary drug development in heart failure: call for hemodynamically neutral therapies
10.1161/circheartfailure.115.002271 · 2015
A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need
10.1016/j.ahj.2005.06.014 · 2006
Mechanisms of atrial fibrillation
2003
Arrhythmias in heart failure: current concepts of mechanisms and therapy
10.1111/j.1540-8167.2000.tb00746.x · 2000
Mechanisms and management of proarrhythmia
10.1016/s0002-9149(98)00472-x · 1998
The Cardiac Arrhythmia Suppression Trial (CAST)
10.1056/nejm198908103210608 · 1989
Sudden cardiac death, genes, and arrhythmogenesis : consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute workshop, part I
10.1161/01.cir.103.19.2361 · 2001
Genetic screening and risk assessment in hypertrophic cardiomyopathy
10.1016/j.jacc.2004.09.032 · 2004
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome
10.1093/hmg/11.3.337 · 2002
Molecular and cellular mechanisms of cardiac arrhythmias
10.1016/s0092-8674(01)00243-4 · 2001
Metabolic abnormalities of the heart in type II diabetes
10.1177/1479164115580936 · 2015
Myocardial blood flow and oxygen consumption in patients with Friedreich’s ataxia prior to the onset of cardiomyopathy
10.1097/01.mca.0000236289.02178.60 · 2007
High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
10.2147/vhrm.s1940 · 2008
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study
10.1161/01.cir.0000140263.20897.42 · 2004
Molecular basis of arrhythmias
10.1161/circulationaha.104.494476 · 2005
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival
10.1016/j.drudis.2011.12.020 · 2012
A new initiative on precision medicine
10.1056/nejmp1500523 · 2015
Opportunities for the cardiovascular community in the precision medicine initiative
10.1161/circulationaha.115.019475 · 2016
The future of cardiovascular therapeutics
10.1161/circulationaha.116.023555 · 2016
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy
10.1161/01.cir.0000019070.70491.6d · 2002
Mechanisms and models in heart failure: a combinatorial approach
10.1161/01.cir.100.9.999 · 1999
Angiotensin-neprilysin inhibition versus enalapril in heart failure
10.1056/nejmoa1409077 · 2014
Molecular physiology of cardiac repolarization
10.1152/physrev.00002.2005 · 2005
10.1016/j.bcp.2009.03.014
10.1016/j.bcp.2009.03.014 · 2009
How were new medicines discovered?
10.1038/nrd3480 · 2011
The discovery of first-in-class drugs: origins and evolution
10.1038/nrd4336 · 2014
Validating therapeutic targets through human genetics
10.1038/nrd4051 · 2013
Cardiac ion channels
10.1146/annurev.physiol.64.083101.145105 · 2002
Mouse models of long QT syndrome
10.1113/jphysiol.2006.118745 · 2007
Targeted point mutagenesis of mouse Kcnq1: phenotypic analysis of mice with point mutations that cause Romano-Ward syndrome in humans
10.1016/j.ygeno.2004.06.007 · 2004
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
10.1016/s0140-6736(12)60312-2 · 2012
Do glia have heart? Expression and functional role for ether-a-go-go currents in hippocampal astrocytes
10.1523/jneurosci.20-10-03915.2000 · 2000
Low penetrance in the long-QT syndrome: clinical impact
10.1161/01.cir.99.4.529 · 1999
Electrical remodeling and arrhythmias in long-QT syndrome: lessons from genetic models in mice
10.1080/17431380410032643 · 2004
Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome
10.1016/s0002-9149(99)90772-5 · 2000
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias
10.1161/01.cir.103.1.89 · 2001
From zebrafish to human: modular medical models
10.1146/annurev.genom.3.031402.131506 · doi-reference
What guides early embryonic blood vessel formation?
10.1002/(sici)1097-0177(199905)215:1<2::aid-dvdy2>3.0.co;2-u · doi-reference
Lipid metabolism in zebrafish
10.1016/s0091-679x(04)76006-9 · doi-reference
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase
10.1126/scitranslmed.3010189 · doi-reference
BMP type I receptor inhibition reduces heterotopic [corrected] ossification
10.1038/nm.1888 · doi-reference
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism
10.1038/nchembio.2007.54 · doi-reference
Central role for GSK3beta in the pathogenesis of arrhythmogenic cardiomyopathy
10.1172/jci.insight.85923 · doi-reference
Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy
10.1126/scitranslmed.3008008 · doi-reference
Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen
10.1161/circulationaha.110.003731 · doi-reference
NOS1AP is a genetic modifier of the long-QT syndrome
10.1161/circulationaha.109.879643 · doi-reference
Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block
10.1161/hh1401.095087 · doi-reference
Refining detection of drug-induced proarrhythmia: QT interval and TRIaD
10.1016/j.hrthm.2005.03.023 · doi-reference
High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafish
10.1152/physiolgenomics.00206.2009 · doi-reference
In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling
10.1093/cvr/cvr350 · doi-reference
In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation
10.1152/ajpheart.00960.2005 · doi-reference
Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors
10.1016/j.bmcl.2008.06.052 · doi-reference
Systematic approaches to toxicology in the zebrafish
10.1146/annurev-pharmtox-010611-134751 · doi-reference
Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation
10.1038/nbt963 · doi-reference
AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression
10.1242/dev.008904 · doi-reference
Rapid behavior-based identification of neuroactive small molecules in the zebrafish
10.1038/nchembio.307 · doi-reference
The zebrafish: heritable disorders in transparent embryos
10.1172/jci118608 · doi-reference
Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases
10.1038/nbt1398 · doi-reference
Genomics. Zebrafish—the canonical vertebrate
10.1126/science.1066652 · doi-reference
Drugs that induce repolarization abnormalities cause bradycardia in zebrafish
10.1161/01.cir.0000061912.88753.87 · doi-reference
High-throughput assay for small molecules that modulate zebrafish embryonic heart rate
10.1038/nchembio732 · doi-reference
Zebrafish-based small molecule discovery
10.1016/j.chembiol.2003.10.003 · doi-reference
In vivo drug discovery in the zebrafish
10.1038/nrd1606 · doi-reference
Animal models of human disease: zebrafish swim into view
10.1038/nrg2091 · doi-reference
Zebrafish: a new model on the pharmaceutical catwalk
10.1002/bies.10326 · doi-reference
Genetic screening in C. elegans identifies rho-GTPase activating protein 6 as novel HERG regulator
10.1016/j.yjmcc.2008.10.015 · doi-reference
Zebrafish as tools for drug discovery
10.1038/nrd4627 · doi-reference
Large-scale prediction and testing of drug activity on side-effect targets
10.1038/nature11159 · doi-reference
Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation
10.1161/circulationaha.114.010403 · doi-reference
Efficacy of amiodarone during long-term treatment of potentially dangerous ventricular arrhythmias in patients with chronic stable ischemic heart disease
10.1016/0002-8703(84)90310-7 · doi-reference
Mechanism of block and identification of the verapamil binding domain to HERG potassium channels
10.1161/01.res.84.9.989 · doi-reference
Efficacy of chronic amiodarone therapy in patients with variant angina pectoris and inhibition of ergonovine coronary constriction
10.1016/0002-8703(82)90526-9 · doi-reference
Pharmacogenomics: challenges and opportunities
10.7326/0003-4819-145-10-200611210-00007 · doi-reference
Animal models for arrhythmias
10.1016/j.cardiores.2005.06.012 · doi-reference
Cardiac myocyte cell cycle control in development, disease, and regeneration
10.1152/physrev.00032.2006 · doi-reference
Origins and fates of cardiovascular progenitor cells
10.1016/j.cell.2008.02.002 · doi-reference